@JNCCN is on Twitter!
Make sure to follow us (twitter.com/JNCCN) to stay updated on NCCN news and articles published in JNCCN.
@JNCCN
Flatiron Health to Incorporate NCCN Chemotherapy Order Templates into OncoEMR
NCCN is collaborating with Flatiron Health to integrate the NCCN Chemotherapy Order Templates (NCCN Templates) into the Flatiron Health OncoEMR electronic health record, starting initially with breast, colon, and non–small cell lung cancers, with plans to expand to additional tumor types.
“Breast, colon, and lung cancers are 3 of the most common cancers in the United States, and the decision to incorporate NCCN Templates, beginning with these 3 diseases, into OncoEMR indeed will enhance the safety and effectiveness of care for many patients in community and academic settings alike,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “NCCN is eager to collaborate with Flatiron Health on this significant endeavor.”
OncoEMR is a cloud-based electronic health record designed specifically for cancer centers. As part of this integration, cancer care providers will be able to easily select the NCCN Templates directly within OncoEMR at the point of care.
“We are pleased to collaborate with NCCN on this new offering, which will enhance the delivery of care for patients across the Flatiron provider network,” said Robert J. Green, MD, Vice President, Clinical Strategy and Senior Medical Director, Flatiron Health. “Seamless, integrated access to the NCCN Templates within OncoEMR will assist physicians in referencing the latest evidence-based treatment regimens at the point of care.”
In addition, OncoEMR will link to NCCN.org so that the NCCN Guidelines are available to end users as a reference. The information contained in the NCCN Templates is based on the NCCN Guidelines. NCCN Templates include chemotherapy and immunotherapy regimens with literature support, supportive care agents, monitoring parameters, and safety instructions. The NCCN Templates enhance patient safety by assisting health care providers with standardization of patient care, reduction in medication errors, and anticipation and management of adverse effects.
NCCN continues to add to the library of chemotherapy order templates to improve the safe and effective use of drugs and biologics in cancer care.
In January 2015, NCCN and Flatiron announced a collaboration to launch a novel oncology outcomes database to provide the opportunity to analyze key quality and outcomes metrics and identify trends and patterns in the care of patients with cancer.
For more information about the NCCN Templates, visit NCCN.org/ordertemplates.
NCCN Receives $2-Million Funding Commitment from ImmunoGen, Inc. to Study Mirvetuximab Soravtansine for Folate Receptor Alpha-Positive Cancers
The NCCN Oncology Research Program (ORP) has been awarded a $2-million grant from ImmunoGen, Inc. to support the advancement of scientific knowledge related to mirvetuximab soravtansine (IMGN853), a potential new treatment for ovarian and other folate receptor alpha (FRα)–positive cancers.
“NCCN ORP values our collaboration with ImmunoGen on this significant research initiative,” said Diane E. Paul, MS, RN, Vice President, NCCN ORP. “This grant and the resulting research will provide investigators from NCCN Member Institutions the opportunity to advance medical research that may translate into improvements in survival and quality of life for patients with cancer.”
According to ImmunoGen, mirvetuximab soravtansine (IMGN853) is a potential new treatment for ovarian, endometrial, breast, and other cancers that highly express FRα. An antibody-drug conjugate (ADC), it comprises an ImmunoGen FRα-targeting antibody attached to the company's potent tubulin-acting agent, DM4. The antibody serves to target the compound specifically to cancer cells expressing FRα, and the DM4 serves to kill these cells.
The first phase of the program will involve the establishment of an NCCN Mirvetuximab Soravtansine Request for Proposals Team, comprising relevant experts from NCCN Member Institutions, to review the existing data and define the study areas appropriate to enhance insight into the potential role of mirvetuximab soravtansine in the treatment of FRα-positive cancers.
The NCCN ORP draws on the expertise of investigators at NCCN Member Institutions and the NCCN Affiliate Research Consortium to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. The NCCN ORP will use the grant from ImmunoGen, Inc. to support investigator-initiated preclinical, clinical, and correlative studies of mirvetuximab soravtansine at NCCN Member Institutions and their affiliate community hospitals. To date, this research model has received more than $54 million in research grants and supported 125 studies that have produced a number of publications in peer-reviewed journals.
ImmunoGen, Inc. is a biotechnology company focused on the development of targeted anticancer therapeutics. The company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company utilizes its ADC technology with its antibodies to create ImmunoGen product candidates and also out-licenses limited rights to use its technology to other companies. Roche's Kadcyla is the first marketed product with ImmunoGen's ADC technology. More information about the company can be found at www.immunogen.com.
To learn more about the NCCN ORP, the NCCN Affiliate Research Consortium, and ongoing clinical trials, visit NCCN.org.
